ARTICLE | Clinical News
Descovy emtricitabine/tenofovir alafenamide regulatory update
April 11, 2016 7:00 AM UTC
FDA approved Descovy emtricitabine/tenofovir alafenamide from Gilead to treat HIV-1 infection in patients ages >=12. Gilead launched Descovy at a wholesale acquisition cost (WAC) of $17,842 last week....